Can Fite Biopharma Ltd (CANF) — Tangible Net Worth Ratio
Can Fite Biopharma Ltd (CANF) has a Tangible Net Worth Ratio of 100.0% as of December 2025. This metric is calculated by deducting intangible assets (ILA0.00) from net assets (ILA5.59 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Can Fite Biopharma Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Can Fite Biopharma Ltd Tangible Net Worth Ratio (2003–2025)
This chart shows how Can Fite Biopharma Ltd's Tangible Net Worth Ratio has changed across 21 annual periods from 2003 to 2025. As of December 2025, the ratio stands at 100.0%, reflecting net assets of ILA5.59 Million with intangible assets of ILA0.00 ILA. See Can Fite Biopharma Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Can Fite Biopharma Ltd (2003–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Can Fite Biopharma Ltd from 2003 to 2025, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see CANF company net worth.
| Year | Tangible NW Ratio | Net Assets (ILA) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | ILA5.59 Million | ILA0.00 | ILA9.52 Million | ▲ +0.0 pp |
| 2024 | 100.0% | ILA5.44 Million | ILA0.00 | ILA9.12 Million | ▲ +0.0 pp |
| 2023 | 100.0% | ILA6.24 Million | ILA0.00 | ILA9.99 Million | ▲ +0.0 pp |
| 2022 | 100.0% | ILA4.47 Million | ILA0.00 | ILA9.28 Million | ▲ +0.0 pp |
| 2021 | 100.0% | ILA14.38 Million | ILA0.00 | ILA20.25 Million | ▲ +0.0 pp |
| 2020 | 100.0% | ILA6.07 Million | ILA0.00 | ILA9.52 Million | ▲ +0.0 pp |
| 2019 | 100.0% | ILA2.44 Million | ILA0.00 | ILA8.17 Million | ▲ +0.0 pp |
| 2018 | 100.0% | ILA3.02 Million | ILA0.00 | ILA7.95 Million | ▲ +0.0 pp |
| 2017 | 100.0% | ILA3.05 Million | ILA0.00 | ILA7.83 Million | ▲ +0.0 pp |
| 2016 | 100.0% | ILA3.87 Million | ILA0.00 | ILA10.17 Million | ▲ +0.0 pp |
| 2015 | 100.0% | ILA10.44 Million | ILA0.00 | ILA17.60 Million | ▲ +0.0 pp |
| 2014 | 100.0% | ILA6.86 Million | ILA0.00 | ILA10.19 Million | ▲ +0.0 pp |
| 2013 | 100.0% | ILA4.46 Million | ILA0.00 | ILA6.63 Million | ▲ +0.0 pp |
| 2011 | 100.0% | ILA3.29 Million | ILA0.00 | ILA4.90 Million | ▲ +0.0 pp |
| 2010 | 100.0% | ILA13.07 Million | ILA0.00 | ILA18.55 Million | ▲ +0.0 pp |
| 2009 | 100.0% | ILA13.49 Million | ILA0.00 | ILA20.10 Million | ▲ +0.0 pp |
| 2008 | 100.0% | ILA14.79 Million | ILA0.00 | ILA21.86 Million | ▲ +0.0 pp |
| 2007 | 100.0% | ILA38.70 Million | ILA0.00 | ILA48.94 Million | ▲ +0.0 pp |
| 2006 | 100.0% | ILA38.34 Million | ILA0.00 | ILA41.76 Million | ▲ +0.0 pp |
| 2005 | 100.0% | ILA35.83 Million | ILA0.00 | ILA37.09 Million | ▲ +0.0 pp |
| 2003 | 100.0% | ILA2.07 Million | ILA0.00 | ILA2.71 Million | — |